SRCIN1 Antibody

What is the expression pattern of SRCIN1 across normal tissues and cancer?

SRCIN1 shows variable expression across human tissues. Immunohistochemistry studies using tissue microarrays have revealed:

• Strong cytoplasmic immunoreactivity (100%) in breast, cerebrum, liver, and skin tissues

• Moderate to strong cytoplasmic expression (80%) in kidney, testis, and stomach

• Lower expression (60%) in lung and minimal expression (20%) in pancreas

• Negative expression in esophagus, ovary, prostate, and uterus

Notably, 80% of normal colorectal tissues show negative SRCIN1 expression, while 84% of colorectal cancer tissues and 100% of CRC metastatic lymph nodes exhibit positive SRCIN1 expression . In contrast, SRCIN1 is downregulated in non-small cell lung cancer (NSCLC) compared to adjacent normal tissues . This differential expression pattern underscores the context-dependent role of SRCIN1 in different cancer types.

What validated applications are available for SRCIN1 antibodies?

SRCIN1 antibodies have been validated for multiple research applications:

• Western blotting (WB): Effective for detecting SRCIN1 protein (approximately 140 kDa) in human cancer cell lines (T-47D, MDA-MB-453), rat and mouse brain tissue lysates

• Immunohistochemistry (IHC-P): Successfully used on paraffin-embedded sections of human tissues (appendicitis, ovarian cancer, placenta, esophagus squamous cancer)

• Immunocytochemistry (ICC): Applied to cultured cells to visualize cellular localization

• Immunofluorescence (IF): Used to examine subcellular distribution

• Flow Cytometry: Validated for cell surface expression analysis

• ELISA: Confirmed for quantitative protein detection

Optimal antibody concentration varies by application, with typical working dilutions ranging from 0.5 μg/mL for Western blot to 1 μg/mL for immunohistochemistry .

How should experiments be designed to investigate SRCIN1's contradictory roles in different cancer types?

When investigating SRCIN1's apparently contradictory functions across cancer types, consider these methodological approaches:

• Comparative expression analysis: Perform systematic comparison of SRCIN1 expression across multiple cancer types using matched tumor and adjacent normal tissues. Western blotting analysis of 10 pairs of matched normal and cancerous colon tissue revealed higher SRCIN1 expression in 70% of tumor samples .

• Context-specific signaling pathway analysis: Examine SRCIN1 interactions with different downstream effectors:

  • In colorectal cancer: Assess interactions with Wnt/β-catenin pathway components

  • In breast cancer: Focus on Src and STAT3 pathway inhibition

  • In non-small cell lung cancer: Examine interactions with miR-657 and the Slug pathway

• Functional validation through gene modulation: Use siRNA knockdown and overexpression experiments across different cell lines representing various cancer types. For example:

  • In CRC cells (LoVo, SW1116): SRCIN1 knockdown induced cell differentiation, increased E-cadherin expression, and caused G0/G1 cell cycle arrest

  • In NSCLC cells (A549, NCI-H1650): SRCIN1 overexpression suppressed proliferation, invasion, and EMT by regulating Slug, E-cadherin, Vimentin, and N-cadherin expression

• Tissue microenvironment considerations: Examine SRCIN1 function in 3D culture systems that better recapitulate in vivo conditions, such as MDCK cysts as a structural model of renal tubules .

What methodological considerations are important when using SRCIN1 antibodies for investigating its role in lipid rafts?

SRCIN1 localization to lipid rafts is critical for its signaling functions. When investigating this aspect:

• Lipid raft isolation protocol optimization:

  • Use appropriate detergent-resistant membrane fractionation techniques

  • Verify fractionation quality with known lipid raft markers

  • The search results indicate CDCP1 (a related protein) controls lipid raft localization of SFKs including Src

• Antibody selection for lipid raft studies:

  • Use antibodies validated for detecting SRCIN1 in its native conformational state

  • Consider using non-denaturing conditions for some applications

  • Verify antibody specificity in fractionated samples

• Mutant constructs as controls:

  • Include SRCIN1 mutants lacking lipid raft localization signals (similar to the CDCP1-CG mutant mentioned in the research)

  • Compare wild-type vs. mutant SRCIN1 localization patterns and functional effects

• Co-localization studies:

  • Perform double immunofluorescence staining of SRCIN1 with established lipid raft markers

  • Use confocal microscopy with appropriate resolution for membrane microdomain visualization

• Functional readouts:

  • Assess how lipid raft disruption (via cholesterol depletion) affects SRCIN1-dependent signaling

  • Compare Src activation in lipid raft vs. non-lipid raft fractions, as shown in the research on related SFK pathways

How can SRCIN1 antibodies be effectively used to study its role in therapeutic resistance?

SRCIN1 has been implicated in therapeutic sensitivity and resistance mechanisms:

• Combination therapy experimental design:

  • In colorectal cancer models, SRCIN1 suppression enhanced sensitivity to 5-fluorouracil (5-FU) both in vitro and in vivo

  • For KRAS-G12C mutant cancers, Src inhibition overcame resistance to KRAS-targeted therapy

  • Design experiments combining SRCIN1 modulation with standard chemotherapeutics or targeted therapies

• Resistance model development:

  • Establish therapy-resistant cell lines through stepwise drug exposure

  • Compare SRCIN1 expression and localization between parental and resistant cells

  • In neuroblastoma, p140Cap/SRCIN1 increased sensitivity to doxorubicin and etoposide treatment

• Mechanistic pathway analysis:

  • Use phospho-specific antibodies to detect activation status of SRCIN1-regulated pathways

  • Examine changes in EMT markers (E-cadherin, N-cadherin, Vimentin) in response to therapy with and without SRCIN1 modulation

  • Assess Wnt/β-catenin pathway activation, as SRCIN1 was shown to induce this pathway in colorectal cancer

• In vivo validation protocols:

  • Utilize xenograft models to assess how SRCIN1 modulation affects therapeutic response

  • Consider patient-derived xenografts to better recapitulate clinical scenarios

  • SRCIN1 knockdown inhibited xenograft tumorigenesis and enhanced effectiveness of 5-FU chemotherapy in established CRC xenografts

What approaches should be used to validate SRCIN1 antibody specificity for specific applications?

Ensuring antibody specificity is critical for reliable research outcomes:

• Multi-method validation approach:

  • Cross-validate results using at least two different antibodies targeting distinct epitopes

  • Compare commercial antibodies with in-house validated reagents when possible

  • Verify antibody specificity across multiple cell lines and tissue types

• Knockdown/knockout controls:

  • Include SRCIN1 knockdown (siRNA/shRNA) or knockout (CRISPR-Cas9) samples

  • The search results show successful validation using SRCIN1 siRNA in LoVo and SW1116 cell lines

  • Western blotting confirmed effective knockdown and overexpression with 70-80% efficiency

• Recombinant protein controls:

  • Use purified recombinant SRCIN1 protein as a positive control

  • Perform peptide competition assays to confirm epitope specificity

  • Consider using tagged recombinant SRCIN1 for dual detection strategies

• Application-specific validation:

  • For IHC: Include multiple tissue types known to express or lack SRCIN1

  • For WB: Confirm appropriate molecular weight (approximately 140 kDa)

  • For IP: Verify pull-down of known SRCIN1 interaction partners

• Cross-species reactivity assessment:

  • Test antibody performance across human, mouse, and rat samples if cross-reactivity is claimed

  • The examined antibodies showed reactivity with human, mouse and rat SRCIN1

What are the best methodological approaches for studying SRCIN1's interaction with microRNAs?

Several microRNAs have been shown to regulate SRCIN1 expression in cancer:

• miRNA target validation techniques:

  • Luciferase reporter assays: Confirm direct targeting of SRCIN1 3'UTR

    • In NSCLC, miR-657 was shown to directly target SRCIN1 using wild-type and mutant 3'UTR luciferase constructs

    • Similarly, miR-665 was demonstrated to target SRCIN1 in ovarian cancer

  • RNA immunoprecipitation (RIP) assays: Verify physical interaction between miRNAs and SRCIN1 mRNA

  • RNA pull-down assays: Confirm binding of specific miRNAs to SRCIN1

• Expression correlation analysis:

  • Perform qPCR to analyze inverse correlation between miRNA and SRCIN1 levels

  • In NSCLC tissues, miR-657 and SRCIN1 showed significant negative correlation (Pearson correlation analysis)

• Functional rescue experiments:

  • Conduct miRNA overexpression with concurrent SRCIN1 rescue experiments

  • Design experiments testing whether SRCIN1 overexpression can reverse miRNA-induced phenotypes

  • In NSCLC, SRCIN1 overexpression partially reversed miR-657's effects on cell proliferation and invasion

• Pathway analysis downstream of miRNA-SRCIN1 interaction:

  • Examine effects on known SRCIN1 pathways (Src, STAT3, Wnt/β-catenin)

  • Assess changes in EMT markers, which are commonly regulated by SRCIN1

  • In NSCLC, the miR-657-SRCIN1 axis was shown to regulate the Slug pathway

What sample preparation protocols optimize SRCIN1 detection in different applications?

For optimal SRCIN1 detection, consider these application-specific protocols:

• Western Blotting:

  • Use 5-20% SDS-PAGE gels for optimal separation of the 140 kDa SRCIN1 protein

  • Apply 50 μg of protein sample under reducing conditions

  • Run electrophoresis at 70V (stacking gel)/90V (resolving gel) for 2-3 hours

  • Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

  • Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

  • Incubate with primary antibody at 0.5 μg/mL overnight at 4°C

  • Wash with TBS-0.1% Tween (3 times, 5 minutes each)

  • Incubate with HRP-conjugated secondary antibody (1:10000 dilution) for 1.5 hours at room temperature

  • Develop using enhanced chemiluminescence detection

• Immunohistochemistry:

  • Perform heat-mediated antigen retrieval in citrate buffer (pH 6.0) for 20 minutes

  • Block tissue sections with 10% goat serum

  • Incubate with primary antibody at 1 μg/ml overnight at 4°C

  • Use biotinylated secondary antibody (30 minutes at 37°C)

  • Develop using Streptavidin-Biotin-Complex with DAB as chromogen

• Cell Fractionation for Lipid Raft Analysis:

  • Use appropriate detergent-resistant membrane isolation protocols

  • Verify fractionation quality with established lipid raft markers

  • Compare protein distribution across fractions

  • Include controls for non-lipid raft membrane fractions

How should researchers address potential discrepancies in SRCIN1 detection across different experimental systems?

When encountering discrepancies in SRCIN1 detection:

• Antibody validation across systems:

  • Verify antibody performance in your specific experimental system

  • Consider testing multiple antibodies targeting different epitopes

  • Assess potential cross-reactivity with related proteins

• Technical optimization for specific tissues/cells:

  • Adjust lysis buffers for different tissue types (brain tissue may require different processing than epithelial tissues)

  • Optimize antigen retrieval methods for different fixation protocols

  • Consider native vs. denatured protein detection methods

• Analysis of SRCIN1 isoforms and post-translational modifications:

  • Investigate potential tissue-specific isoforms or modifications

  • Use phospho-specific antibodies when investigating signaling activity

  • Consider proteolytic processing, as SRCIN1 may undergo cleavage similar to related proteins

• Control for contextual protein expression:

  • Include positive and negative control samples in each experiment

  • Use recombinant SRCIN1 as a standard for quantitative comparisons

  • Document experimental conditions thoroughly to enable troubleshooting

The research demonstrates significant variation in SRCIN1 expression and function across tissue types and cancer contexts, so methodological consistency is crucial for reliable results .

How can SRCIN1 antibodies be used to investigate its role in cancer progression and metastasis?

SRCIN1 plays complex roles in cancer progression that can be investigated using the following approaches:

• Multi-step cancer progression analysis:

  • Compare SRCIN1 expression across normal tissue, primary tumors, and metastatic lesions

  • In colorectal cancer, SRCIN1 was negative in 80% of normal tissues but positive in 84% of primary tumors and 100% of metastatic lymph nodes

  • Use tissue microarrays to assess SRCIN1 expression across large sample sets

• Invasion and migration functional assays:

  • Perform Transwell invasion assays with SRCIN1 knockdown or overexpression

  • Conduct wound healing assays to assess migration capacity

  • SRCIN1 overexpression suppressed the invasiveness of A549 and NCI-H1650 NSCLC cells in vitro

• EMT marker analysis:

  • Examine E-cadherin, N-cadherin, Vimentin, and Slug expression following SRCIN1 modulation

  • SRCIN1 knockdown in CRC cells increased E-cadherin expression, suggesting induction of differentiation

  • In NSCLC, SRCIN1 overexpression increased E-cadherin while reducing Slug, Vimentin, and N-cadherin

• Signaling pathway activation markers:

  • Assess Src activity (phospho-Src) and downstream effectors

  • Examine STAT3 phosphorylation status

  • Evaluate β-catenin nuclear localization to assess Wnt pathway activation

  • SRCIN1 was shown to induce Wnt/β-catenin signaling in CRC cells

• In vivo metastasis models:

  • Utilize tail vein injection or orthotopic implantation models

  • Analyze spontaneous metastasis in xenograft models

  • SRCIN1 knockdown in neuroblastoma reduced spontaneous lung metastasis formation

What experimental designs best demonstrate SRCIN1's role in therapeutic sensitivity?

To investigate SRCIN1's impact on therapeutic responses: